HBV safety with long-acting HIV therapy for people with HIV
Official title: LANCET-HBV: Hepatitis B Infection in the Era of Long-Acting ART
Funded at University of California Los Angeles · NIH-11470595 · Data updated 2026-11-12
A study to understand how long-acting HIV meds affect hepatitis B in people living with HIV and how to best monitor and protect them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | August 4, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $673,177 |
| NIH project number | 1R01AI203549-01 |
| Project ID | NIH-11470595 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with HIV who are participating in the ACTG LANCET trial and have prior HBV exposure or non-immunity.
✕Less likely to help
People not affected by HIV or HBV status or not involved in the LA-ART transition may not benefit.
What this research studies
This project follows people with HIV who switch to long-acting HIV meds to see how HBV behaves when HBV-active drugs may be stopped. It combines clinical data, lab tests, and behavioral research to learn who is at risk of HBV reactivation or new HBV infection during the switch. Researchers will use data from an existing clinical trial and add studies to understand biology, patient knowledge, and cost-effective screening strategies. The work aims to guide safer switch practices and improve care for people with HIV who have prior HBV exposure or non-immunity.
Why it matters
Potential benefit: If successful, the study could lead to safer switching strategies and better HBV monitoring for people with HIV using long-acting therapies.
How similar studies have gone: Previous observational data suggest this is a relevant area, but detailed incidence and mechanisms are still being defined; this study builds on that knowledge.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Bhattacharya, Debika — University of California Los Angeles
- Study coordinator: Bhattacharya, Debika
Related research
Other NIH-funded projects on the same topics.
-
HBV cure clues in people with and without HIV
This project studies how HBV-specific B and T cell responses relate to curing hepatitis B in people with and without HIV.
-
HBV cure factors in people with and without HIV
This project studies how HBV-specific immune cells behave during treatment and whether people with HIV respond differently than those without HIV.
-
HBV prevention in community pharmacies: a first step in a low-resource setting
This pilot project tests whether hepatitis B screening and vaccination can be integrated into everyday community pharmacy services to reach more people.
-
Blood markers to catch early liver cancer in Hispanic people with hepatitis B
This project will see if a blood test can find liver cancer earlier in Hispanic people who have chronic hepatitis B.
-
Early blood markers to find hepatitis B–related liver cancer in Hispanics
This project will use immune-related blood markers to find liver cancer earlier in people with chronic hepatitis B, focusing on Hispanic adults.
-
Antiviral Therapy and HBV DNA Integration in Chronic Hepatitis B
This project looks at how existing HBV drugs may influence the way HBV DNA becomes integrated into the liver cells’ DNA in people with chronic hepatitis B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.